Background:
This is a randomized, superiority, double blind, placebo-controlled, multicenter study comparing evolocumab 420mg
SC vs. placebo administered in the acute phase of ACS. The aim is to evaluate the effectiveness of the PCSK9 inhibitor
evolocumab as compared with placebo for reduction of LDL-C levels within 8 weeks in patients receiving guideline-
recommended high-intensity statin treatment (atorvastatin 40mg QD).
Sponsor: Inselspital Bern, Prof. Dr. Stephan Windecker
Trial Registration No:
NCT03287609 (clinicaltrials.gov) Link
Trial Status:
recruiting
Enrolling Centers:
Bern, Basel, Fribourg, Genf, Lausanne, Lugano, Zürich
Core Study Team:
This is a randomized, superiority, double blind, placebo-controlled, multicenter study comparing evolocumab 420mg
SC vs. placebo administered in the acute phase of ACS. The aim is to evaluate the effectiveness of the PCSK9 inhibitor
evolocumab as compared with placebo for reduction of LDL-C levels within 8 weeks in patients receiving guideline-
recommended high-intensity statin treatment (atorvastatin 40mg QD).
Sponsor: Inselspital Bern, Prof. Dr. Stephan Windecker
Trial Registration No:
NCT03287609 (clinicaltrials.gov) Link
Trial Status:
recruiting
Enrolling Centers:
Bern, Basel, Fribourg, Genf, Lausanne, Lugano, Zürich
Core Study Team:
© Christian Mueller, 2012 - 2019 │ Disclaimer │ Imprint │ Webmaster │ Last Update: January 2019
